Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Royce & Associates LP

Royce & Associates LP reduced its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 5.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 374,119 shares of the biopharmaceutical company’s stock after selling 21,563 shares during the quarter. Royce & Associates LP owned approximately 0.29% of Dynavax Technologies worth $4,168,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. ProShare Advisors LLC grew its holdings in Dynavax Technologies by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 35,269 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 2,691 shares during the period. Vanguard Group Inc. grew its holdings in Dynavax Technologies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after purchasing an additional 126,458 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Dynavax Technologies by 4.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 150,265 shares of the biopharmaceutical company’s stock worth $1,866,000 after purchasing an additional 5,934 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Dynavax Technologies by 11.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 95,537 shares of the biopharmaceutical company’s stock worth $1,186,000 after purchasing an additional 9,839 shares during the period. Finally, Kynam Capital Management LP grew its stake in shares of Dynavax Technologies by 180.0% during the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after buying an additional 2,725,397 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $11.69 on Tuesday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 89.93 and a beta of 1.34. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01. The company’s 50-day simple moving average is $11.39 and its 200-day simple moving average is $11.31. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Analyst Upgrades and Downgrades

DVAX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.